These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 36094691)

  • 1. Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
    Murphy BL; Yi M; Gutierrez Barrera AM; Tripathy D; Hunt KK; Arun BK
    Ann Surg Oncol; 2023 Mar; 30(3):1663-1668. PubMed ID: 36094691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Testing Among Breast Cancer Patients in the Eastern Region of Saudi Arabia: Single-Center Experience.
    Ghareeb GA; Nass ZA; Abu-Grain S; Alnaji A; Almohanna H; Nasser HAS; Al Shahrani S
    J Epidemiol Glob Health; 2024 Sep; 14(3):1351-1357. PubMed ID: 39256315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women.
    Prokurotaite E; Condorelli M; Dechene J; Bouziotis J; Lambertini M; Demeestere I
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients.
    Nizic-Kos T; Krajc M; Blatnik A; Stegel V; Skerl P; Novakovic S; Gazic B; Besic N
    Ann Surg Oncol; 2021 May; 28(5):2561-2570. PubMed ID: 33030641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.
    Chavarri-Guerra Y; Villarreal-Garza C; Ferrigno AS; Mohar A; Aguilar D; Alvarez-Gomez RM; Gallardo-Alvarado L; Del Toro-Valero A; Quintero-Beulo G; Gutierrez-Delgado F; Rodriguez-Olivares JL; Ochoa-Chavez MF; Gutierrez-Seymour G; Castillo D; Herzog J; Weitzel JN
    Salud Publica Mex; 2022 Feb; 64(1):41-48. PubMed ID: 35438911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
    BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second Primary Breast Cancer in Young Breast Cancer Survivors.
    Brantley KD; Rosenberg SM; Collins LC; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Warner E; Come SE; Zheng Y; Kirkner GJ; Snow C; Winer EP; Partridge AH
    JAMA Oncol; 2024 Jun; 10(6):718-725. PubMed ID: 38602683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
    Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
    Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
    Murphy BL; Yi M; Arun BK; Gutierrez Barrera AM; Bedrosian I
    Ann Surg Oncol; 2020 Nov; 27(12):4613-4621. PubMed ID: 32720048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
    Tsai ML; Knaack M; Martone P; Krueger J; Baldinger SR; Lillemoe TJ; Susnik B; Grimm E; Olet S; Rueth N; Swenson KK
    Clin Breast Cancer; 2021 Feb; 21(1):47-56. PubMed ID: 32739136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.
    Fulk K; Milam MR; Li S; Yussuf A; Black MH; Chao EC; LaDuca H; Stany MP
    Gynecol Oncol; 2019 Mar; 152(3):612-617. PubMed ID: 30612783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study.
    Han SA; Kim SW; Kang E; Park SK; Ahn SH; Lee MH; Nam SJ; Han W; Bae YT; Kim HA; Cho YU; Chang MC; Paik NS; Hwang KT; Kim SJ; Noh DY; Choi DH; Noh WC; Kim LS; Kim KS; Suh YJ; Lee JE; Jung Y; Moon BI; Yang JH; Son BH; Yom CK; Kim SY; Lee H; Jung SH;
    Fam Cancer; 2013 Mar; 12(1):75-81. PubMed ID: 23131904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
    Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
    Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from London Regional Clinical Genetics services over a 5-year period on germline
    Garrett A; Talukdar S; Izatt L; Brady AF; Whyte S; Josephs KS; Shanmugasundaram M; Guillemot LS; Vakili D; Ey S; Ahmed M
    J Med Genet; 2022 Jun; 59(6):554-558. PubMed ID: 34266904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
    BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
    Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    John CS; Fong A; Alban R; Gillen J; Moore KM; Walsh CS; Li AJ; Rimel BJ; Amersi F; Cass I
    Gynecol Oncol; 2022 Jan; 164(1):202-207. PubMed ID: 34862065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.